The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function
This study has been completed.
Information provided by (Responsible Party):
Yerem Yeghiazarians, University of California, San Francisco
First received: February 21, 2008
Last updated: September 16, 2011
Last verified: September 2011
Our main hypothesis is that EPC function is impaired in some populations with high cardiovascular risk as a result of reduced eNOS-dependent NO production.
||Observational Model: Cohort
Time Perspective: Prospective
||The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function
Biospecimen Retention: Samples Without DNA
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||December 2010 (Final data collection date for primary outcome measure)
High cardiovascular risk age over 61 years.
Low Cardiovascular risk age over 61.
High cardiovascular risk age over 25 but under 61.
Low cardiovascular risk age over 25 under 61.
To determine if a correlation exists between EPC function and eNOS-dependent NO production in EPCs from populations with high versus low cardiovascular risk:
- High and low cardiovascular risk subjects will be identified based on age or history of cardiovascular disease. Endothelial function will be measured by ultrasound.
- EPCs will be isolated from peripheral blood of these subjects. EPC function will be assessed by measuring adhesion to endothelium, migration, proliferation, and differentiation, and compared to their expression and activity of eNOS.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Population in both low and high risk groups should represent the general population.
- Willing and able to give written informed consent and comply with study requirements
- Adult of 18 years or older
- Subjects willing to provide blood and tissue samples
- Failure to give informed consent.
- Those unable to consent for themselves.
- Those who cannot read English.
- Patients on Viagra, Levitra, or Cialis
- Patients with malignant disease
- Patients with hematological abnormalities
- Patients with fevers of unknown origin
- Severe comorbidity or alcohol/drug dependence
- Women who are post-menopausal and on hormone replacement therapy, or premenopausal and on birth control pills (premenopausal women will be screened verbally and then by assay of LH and FSH levels in blood samples to identify women in the follicular phase of their menstrual cycle, to reduce variability)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00627068
|UCSF, Department of Cardiology
|San Francisco, California, United States, 94143 |
University of California, San Francisco
||Yerem Yeghiazarians, M.D
||University of California, San Francisco
No publications provided
||Yerem Yeghiazarians, Assistant Clinical Professor, University of California, San Francisco
History of Changes
|Other Study ID Numbers:
|Study First Received:
||February 21, 2008
||September 16, 2011
||United States: Institutional Review Board
Keywords provided by University of California, San Francisco:
Subjects with high cardiovascular risk
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on February 27, 2015